A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.
Jayson, Gordon C
Ledermann, J A
AffiliationMedical Oncology, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, UK.
MetadataShow full item record
AbstractSagopilone, the first fully synthetic epothilone, has shown promising preclinical activity in tumour models. This open-label randomised phase II study investigated two infusion schedules of sagopilone in women with ovarian cancer.
CitationA phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. 2011, 22 (11):2411-6 Ann Oncol
JournalAnnals of Oncology